Clinical trials: Cancer of Brain
Radiotherapy, Brain Metastases
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases
Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease.
- Conditions
- Radiotherapy, Brain Metastases, Sensitivity, Radionecrosis
- Trial name
- NCT04700748
- Testing
- Brain metastases radiation
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Lund University Hospital
Glioma, Cognition Disorders
Cognitive Rehabilitation of Glioma Patients
The purpose of this study is to determine whether cognitive rehabilitation is effective in patients with gliomas (brain tumour), by comparing direct and follow-up neuropsychological functioning and quality of life of the…
- Trial name
- NCT00256425
- Testing
- Cognitive rehabilitation
- Where
- 9 sites in Netherlands
- Volunteers
- 140 people
- Sponsor
- UMC Utrecht
EGFR Positive Non-small Cell Lung Cancer, Brain Metastases
A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases
Almonertinib is a three-generation epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), which has shown competitive potential in the second-line treatment against first-generation TKIs.
- Trial name
- NCT04643847
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- First People's Hospital of Hangzhou
Solid Tumors With PTCH1 Loss-of-function Mutations
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
This study employs a 2-stage design that aims to evaluate the efficacy and safety of ENV- 101, a potent Hedgehog (Hh) pathway inhibitor, in patients with refractory advanced solid tumors characterized by loss of function (LOF)…
- Trial name
- NCT05199584
- Testing
- ENV-101 (taladegib)
- Where
- 16 sites in United States
- Volunteers
- 20 people
- Sponsor
- Endeavor Biomedicines, Inc.
Brain and Central Nervous System Tumors
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT00897663
- Testing
- gene expression analysis, microarray analysis, protein expression analysis
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma, Gliosarcoma
Ph I Dasatinib + Erlotinib in Recurrent MG
Primary: To determine maximum tolerated dose \& dose limiting toxicity of dasatinib when combined w erlotinib among pts w recurrent MG Secondary: To further evaluate safety \& tolerability of dasatinib + erlotinib To evaluate…
- Trial name
- NCT00609999
- Testing
- Erlotinib and Dasatinib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Duke University
Glioblastoma (GBM)
Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma
This study aims to see if reducing blood sugar and increasing ketones (a metabolic product that comes from using fats for energy) can increase survival and enhance the the effects of standard radiation and chemotherapy treatments…
- Trial name
- NCT02046187
- Testing
- Ketogenic Diet, Radiation therapy, Temozolomide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Postoperative Delirium
Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors
Neurosurgery is a risk factor for delirium. Dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality.
- Trial name
- NCT06164314
- Testing
- Dexmedetomidine
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Beijing Tiantan Hospital
Brain and Central Nervous System Tumors
TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma
RATIONALE: The TP-38 toxin can locate tumor cells and kill them without harming normal cells. Giving TP-38 toxin directly into the tumor may kill more tumor cells.
- Trial name
- NCT00074334
- Testing
- TGFa-PE38 immunotoxin, conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…
- Trial name
- NCT00492687
- Testing
- carboplatin, tamoxifen citrate, temozolomide
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Melanoma
PD-L1 PET Imaging in Melanoma Patients
This is a feasibility study for the use of [18F]PD-L1 as a PET tracer that will be conducted in a single center. The study consists of two phases.
- Trial name
- NCT03520634
- Testing
- PD-L1 PET imaging
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- University Medical Center Groningen
Meige Syndrome, Meigs Syndrome
A Comparative Study of GPI's DBS and Pallidotomy in the Treatment of Meige Syndrome
In this study, we will compare the degree of postoperative symptom improvement, postoperative complication rate, postoperative quality of life improvement degree of patients with Meige syndrome undergoing pallidotomy (unilateral…
- Conditions
- Meige Syndrome, Meigs Syndrome, Meige Disease, Meig Syndrome
- Trial name
- NCT04618887
- Testing
- pallidotomy, deep brain stimulation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Alzheimer Disease, Dementia
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05522387
- Testing
- XPro1595
- Where
- 4 sites in Australia
- Volunteers
- 11 people
- Sponsor
- Inmune Bio, Inc.
Brain Tumor Adult
Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
This is a non-randomized, purely observational, feasibility study to detect metabolic changes in patients with brain malignancy using a novel hyperpolarized [1-13C]pyruvate MRSI.
- Trial name
- HPCIM (NCT03067467)
- Testing
- Hyperpolarized 13C-Pyruvate, Gadolinium
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Texas Southwestern Medical Center
Brain Tumors
A Case-Referent Study of Brain Tumors in Adults
The etiology of brain tumors is poorly understood. Due, in part, to public concern about a postulated relationship between the use of cellular telephones or other increasingly prevalent environmental exposures and the incidence…
- Trial name
- NCT00339300
- Where
- United States
- Volunteers
- 1,581 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor Malignancies, Brain Metastasases
Exploring the Feasibility of Cerebrospinal Fluid (CSF) and Blood Plasma Liquid Biopsy in Patients With Metastatic Solid Tumours and Primary Central Nervous System (CNS) Tumours: A Pilot Study
This is a prospective, single-centre feasibility study of CSF ctDNA conducted at the Sunnybrook Odette Cancer Centre (SOCC), Toronto, Canada, including multiple solid tumor, stratified into cohorts according to CNS disease…
- Conditions
- Solid Tumor Malignancies, Brain Metastasases, Leptomeningeal Disease (LMD), Central Nervous System
- Trial name
- ECLIPSE (NCT07476781)
- Testing
- One time CSF and blood sample
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- Sunnybrook Health Sciences Centre
Amyotrophic Lateral Sclerosis, Brainstem Stroke
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit
This project adds to non-invasive BCIs for communication for adults with severe speech and physical impairments due to neurodegenerative diseases.
- Conditions
- Amyotrophic Lateral Sclerosis, Brainstem Stroke, Muscular Dystrophies, Parkinson's Disease and Parkinsonism
- Trial name
- BCI-FIT (NCT04468919)
- Testing
- BCI-FIT multi-modal access, BCI-FIT adaptive signal modeling, BCI-FIT active querying
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Glioma
Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas
The purpose of this study is to test the effectiveness and safety of the NovoTTF-200A device in patients with low-grade glioma when it's used by itself or used together with temozolomide.
- Trial name
- NCT02507232
- Testing
- NovoTTF-200A, Temozolomide
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Santosh Kesari
Breast Cancer, Brain Metastases
Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China
The objective of this study is to evaluate the efficacy of combination of palbociclib, trastuzumab and pyrotinib with fulvestrant in ER/PR positive and HER2-positive breast cancer patients with brain metastasis.
- Trial name
- NCT04334330
- Testing
- Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
- Where
- 2 sites in China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Breast Cancer, Brain Metastases
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
The goal of this interventional study is to optimize the protocol of FES PET/CT in Estrogen Receptor positive Breast cancer patients with Brain metastases.
- Trial name
- NCT06072807
- Testing
- Brain Imaging with 18F-FES
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.